Abstract
Synopsis: Hypercholesterolemic patients at risk for coronary heart disease (CHD) may require up-titration of ongoing statin therapy or addition of complementary lipid-lowering drugs to achieve guideline recommended low-density lipoprotein cholesterol (LDL-C) levels. Previous studies have not assessed LDL-C lowering of ezetimibe added to rosuvastatin starting doses. Although ezetimibe/simvastatin was recently shown to reduce a composite of major cardiovascular events commensurate with the degree of LDL-C lowering achieved in patients with advanced chronic kidney disease (SHARP trial), clinical benefit of ezetimibe add-on beyond statin alone awaits results from the ongoing IMPROVE-IT trial.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call